Welcome to our dedicated page for Pulse Biosciences news (Ticker: PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.
Pulse Biosciences, Inc. (PLSE) is a pioneering clinical-stage electroceutical company focused on the commercial application of its proprietary Nano-Pulse Stimulation (NPS) technology. Headquartered in Hayward, CA, the company's core mission is to leverage this novel technology to improve and extend patient lives, addressing the distinct needs of patients and physicians alike.
Nano-Pulse Stimulation Technology
NPS is a cutting-edge, non-thermal, drug-free energy-based technology that utilizes ultra-short nanosecond electrical pulses to impact cell membranes and intracellular structures. This method promotes unique cellular behaviors and can induce specific immune responses, opening up a myriad of therapeutic possibilities. Unlike conventional treatments, NPS delivers electrical pulses in billionths of a second, providing targeted effects without damaging surrounding tissues.
Applications and Innovations
Pulse Biosciences is actively exploring the potential of its NPS technology across various medical fields. Key areas of investigation include immuno-oncology, where NPS may be used to treat cancer by modulating the immune system's response, and dermatology, for treatments that require precise, non-invasive interventions. The technology's unique biologic effects position it as a promising solution for conditions lacking optimal treatments.
Recent Achievements and Projects
The company has made significant strides in both preclinical and clinical studies, demonstrating the safety and efficacy of NPS technology. Recent projects have focused on refining device capabilities, enhancing treatment protocols, and expanding the scope of applications. Partnerships with leading medical institutions and ongoing collaborations with researchers underscore Pulse Biosciences' commitment to innovation.
Financial Condition
Pulse Biosciences generates substantial revenue primarily from the sale of its systems in North America. The company continues to invest in research and development to further advance its technology and explore new market opportunities.
For those looking to stay updated on the latest developments, performance, and news related to Pulse Biosciences, Inc., StockTitan provides a comprehensive and timely resource.
Pulse Biosciences, Inc. (NASDAQ: PLSE) has updated its FDA 510(k) submission to include treatment of sebaceous hyperplasia using the CellFX® System. Originally submitted in December 2021, the application received an Additional Information letter from the FDA on February 5, 2022, citing insufficient clinical evidence. The company plans to meet with the FDA in Q1 2022 to discuss the next steps, which may require more clinical data or a new submission. The CellFX System is currently approved in Europe for several dermatological conditions but faces challenges in the U.S. market.
Pulse Biosciences, Inc. (Nasdaq: PLSE) has announced its participation in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. The company will host investor meetings on February 15-16, 2022. Pulse Biosciences specializes in bioelectric medicine, focusing on health innovations to enhance patient quality of life. Their flagship product, the CellFX® System, utilizes proprietary Nano-Pulse Stimulation™ technology to effectively treat various dermatologic conditions while preserving surrounding tissues. For more details, visit pulsebiosciences.com.
Pulse Biosciences (PLSE) announced preliminary unaudited financial results for Q4 2021, estimating full-year revenue between
Pulse Biosciences, Inc. (NASDAQ: PLSE) announced its participation in the Stephens Annual Investment Conference in Nashville, Tennessee, scheduled for December 2, 2021. Management will engage in a fireside chat at 2:00 PM PT / 4:00 PM CT. Interested individuals can access the live and recorded webcast via the company’s website.
Pulse Biosciences specializes in bioelectric medicine, leveraging its CellFX® System and Nano-Pulse Stimulation™ technology to improve dermatologic outcomes.
Pulse Biosciences, Inc. (Nasdaq: PLSE) announced its third quarter 2021 financial results, reporting revenue of $574,000, with 12 Controlled Launch Program participants opting to acquire CellFX Systems for commercial use. The company onboarded a total of 68 participants and completed patient enrollment for key clinical studies. Operating expenses increased to $14.1 million, with a GAAP net loss of $14.3 million. Cash reserves totaled $42 million as of September 30, 2021. The company aims to expand the CellFX System's applications beyond dermatology.
Pulse Biosciences, Inc. (NASDAQ: PLSE) announced its participation in the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 1:40 pm PT / 4:40 pm ET. The company, known for its innovative bioelectric medicine, aims to enhance patient care through its CellFX® System and Nano-Pulse Stimulation™ (NPS™) technology. The CellFX System treats dermatologic conditions effectively while preserving surrounding tissue. Interested parties can access the on-demand webcast via the Company’s website.
Pulse Biosciences, Inc. (NASDAQ: PLSE) will release its financial results for Q3 2021 on November 15, 2021, after market close. A conference call is scheduled at 1:30 PM PT for investors to discuss the results. The company is known for its innovative Nano-Pulse Stimulation™ (NPS™) technology, with its first commercial product, the CellFX® System, addressing dermatologic conditions. The system offers a multi-application platform with a utilization-based revenue model, aiming to enhance patient care and outcomes.
Pulse Biosciences, Inc. (NASDAQ: PLSE) announced the appointment of Laureen DeBuono to its Board of Directors, succeeding Kenneth Clark, who has resigned. DeBuono brings extensive executive experience in driving growth and shareholder value in life sciences and medical technology sectors. She has previously held positions at Rodan+Fields and served as CEO of govino, LLC. Her appointment aims to enhance the commercial growth of the CellFX® System in dermatology and expand the company’s multi-specialty bioelectric medicine profile.
Pulse Biosciences (NASDAQ: PLSE) announces its participation in the H.C. Wainwright Global Investment Conference on September 14, 2021. Management will hold one-on-one meetings and the event will feature a presentation webcast available starting on September 13, 2021, at 7:00 am ET. The company's CellFX® System, utilizing Nano-Pulse Stimulation™ technology, aims to improve dermatologic outcomes by treating various conditions while preserving adjacent non-cellular tissue. More information can be found on CellFX.com.
Pulse Biosciences (Nasdaq: PLSE) announces the appointment of Mitchell E. Levinson as the new Chief Strategy Officer, alongside his existing position on the board. Levinson, a veteran in the medical device industry with over 30 years of experience, aims to drive the company's expansion into multiple specialties, leveraging the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology. This strategic move is expected to enhance the company's dermatology business and facilitate broader applications of NPS technology, addressing unmet healthcare needs.
FAQ
What is the current stock price of Pulse Biosciences (PLSE)?
What is the market cap of Pulse Biosciences (PLSE)?
What is Pulse Biosciences, Inc.?
What is Nano-Pulse Stimulation (NPS) technology?
What are the primary applications of NPS technology?
Where is Pulse Biosciences, Inc. headquartered?
How does NPS technology differ from traditional treatments?
What recent achievements has Pulse Biosciences made?
What are the financial sources for Pulse Biosciences?
How does Pulse Biosciences contribute to medical innovation?
What is the mission of Pulse Biosciences?
How can I get the latest updates on Pulse Biosciences?
